Agentix Corp posts quarterly loss and severe cash strain

Agentix Corp, a clinical-stage biotechnology company focused on metabolic diseases, reported another loss for the quarter ended June 30, 2026 with no revenue.

Rhea-AI Filing Summary

Agentix Corp, a clinical-stage biotechnology company focused on metabolic diseases, reported another loss for the quarter ended June 30, 2026 with no revenue. Operating expenses fell to $95,504 from $200,342 a year earlier, mainly due to reduced research and development spending, leading to a narrower net loss of $117,674 versus $185,824.

The balance sheet is highly stressed, with cash of $38, total assets of $38, current liabilities of $3,713,831, and a stockholders’ deficit of $(3,713,793). Related-party payables totaled over $2.45 million, and a related-party mezzanine note of $379,700 is secured by substantially all company assets and accrues interest at 2% per month after an initial period.

Management states there is substantial doubt about the company’s ability to continue as a going concern and indicates a need for additional equity or debt financing, which could dilute existing shareholders or carry unfavorable terms. Management also concluded that disclosure controls and procedures were not effective as of June 30, 2026.

Positive

• Quarterly net loss decreased to $117,674 from $185,824 year over year, reflecting significantly lower operating expenses.
• Operating cash outflow for the quarter was limited to $26,372, indicating tight cost control in a period with no revenue.

Negative

• Company reports cash of $38, total assets of $38, and a working capital deficit of $3,713,793, raising acute liquidity concerns.
• Management discloses substantial doubt about the ability to continue as a going concern due to recurring losses and severe capital deficiency.
• A related-party mezzanine note of $379,700 bears interest at 2% per month and is secured by substantially all assets, increasing financial risk.
• Disclosure controls and procedures were deemed not effective as of June 30, 2026, highlighting weaknesses in financial reporting oversight.
• Accumulated deficit reached $7,124,838 with no revenue generated, underscoring prolonged pre-commercial status and dependence on external financing.

Filing Explained

A $379,700 related-party note remains senior to common equity on substantially all company assets through September 30, 2026.

As a Form 10-Q, this is the company’s unaudited interim report; it records no common stock issued for services during the quarter, so no completed issuance of that type is disclosed.

The funding need remains prospective: management says it must raise funds and that an equity raise could dilute existing holders, meaning additional shares would reduce their percentage ownership; the filing gives no amount, equity price, or terms for a new raise.

The equity note lists 40,066,951 shares issued and outstanding and 357,102 shares as common stock to be issued at June 30, 2026. Separately, the related-party note has $379,700 principal outstanding, is extended to September 30, 2026, accrues interest at 2% per month after its initial 30-day period, and is secured by substantially all company assets.

Although the filing says the company is not currently subject to legal proceedings, it separately discloses vendor correspondence alleging approximately $44,991 remains payable and stating that formal debt-recovery proceedings may follow.

The September 30, 2026 note date and any subsequent filing reporting financing terms, share issuance, repayment, or a formal proceeding are the specific checkpoints for resolving these open mechanics.

Key Figures

Net loss: $117,674 Net loss prior year quarter: $185,824 Cash balance: $38 +5 more

8 metrics

Net loss $117,674 Three months ended June 30, 2026

Net loss prior year quarter $185,824 Three months ended June 30, 2025

Cash balance $38 As of June 30, 2026

Current liabilities $3,713,831 As of June 30, 2026

Stockholders' deficit $(3,713,793) As of June 30, 2026

Accumulated deficit $7,124,838 As of June 30, 2026

Net cash used in operating activities $26,372 Three months ended June 30, 2026

Related-party note principal $379,700 Gray’s Peak mezzanine note outstanding as of June 30, 2026

Key Terms

going concern, mezzanine secured notes, stockholders' deficit, smaller reporting company, +2 more

6 terms

going concern financial

"These factors raise substantial doubt about the Company’s ability to continue as a going concern."

Going concern is the accounting assumption that a company will keep operating and meeting its obligations for the foreseeable future. The phrase matters most when a company or its auditors disclose substantial doubt about it, a formal warning that the business may not have enough resources to continue without raising money, restructuring, or selling assets. That language in a filing or press release signals elevated financial risk.

mezzanine secured notes financial

"the Company entered into two separate Mezzanine Secured Notes (the “Notes”) in principal amounts..."

stockholders' deficit financial

"Total stockholders' deficit | | | ( 3,713,793 | )..."

When a company's total liabilities exceed its total assets, the owner's equity becomes negative and is reported as a stockholders' deficit. It shows that, on paper, the business owes more than it owns — like a homeowner whose mortgage balance is larger than the home's market value. Investors watch this because it signals financial strain, higher risk of dilution or default, and can limit a company's ability to pay dividends, borrow, or grow.

smaller reporting company regulatory

"As a smaller reporting company (as defined in Rule 12b-2 of the Exchange Act)..."

A smaller reporting company is a publicly traded firm that meets regulatory size tests allowing it to provide abbreviated financial disclosures and compliance filings compared with larger companies. For investors, that means financial statements and notes may be less detailed, which can make it harder to compare performance or spot risks—think of reading a short summary instead of a full report when deciding whether to buy or hold a stock.

disclosure controls and procedures regulatory

"we evaluated the effectiveness of the design and operation of our disclosure controls and procedures..."

Policies, routines and internal checks a public company uses to identify, collect and verify information that must appear in its financial reports and public filings, and to make sure that material news is disclosed accurately and on time. Investors care because effective controls increase confidence that the company’s reported numbers and disclosures are reliable and reduce the risk of surprises, much like a building’s inspection and alarm system helps occupants trust the structure’s safety.

R&D tax credits financial

"including without limitation all R&D tax credits, goods, tangible property, machinery..."

R&D tax credits are government incentives that return part of a company’s spending on research and development, like a discount or refund for investing in new products or processes. They matter to investors because they lower effective costs, boost cash flow and profitability, and can extend a company’s runway for innovation—factors that affect earnings, valuation and the likelihood a business can turn research into future revenue.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How did Agentix Corp (AGTX) perform financially in the quarter ended June 30, 2026?

Agentix Corp reported a net loss of $117,674 for the quarter ended June 30, 2026, improved from a $185,824 loss a year earlier. The company generated no revenue, and reduced expenses, particularly research and development, drove the smaller loss.

What is the liquidity position of Agentix Corp (AGTX) as of June 30, 2026?

As of June 30, 2026, Agentix Corp held $38 in cash, had total assets of $38, current liabilities of $3,713,831, and negative working capital of $3,713,793. This severe imbalance creates substantial financing pressure and raises significant liquidity risk.

Why does Agentix Corp (AGTX) express substantial doubt about continuing as a going concern?

Management cites an accumulated deficit of $7,124,838, a quarterly net loss of $117,674, negative working capital of $3,713,793, and cash of $38 as of June 30, 2026. These factors led to disclosure of substantial doubt about the company’s ability to continue operating.

What related-party financing obligations does Agentix Corp (AGTX) have?

Agentix Corp owes related parties $2,455,276 in accounts payable and has a mezzanine note of $379,700 to a Gray’s Peak affiliate. The note accrues interest at 2% per month after an initial period and is secured by substantially all company assets.

Are Agentix Corp’s (AGTX) disclosure controls and procedures effective?

Management, including the CEO and CFO, concluded that disclosure controls and procedures were not effective as of June 30, 2026. Despite this, they reported no material changes in internal control over financial reporting during the quarter.

Does Agentix Corp (AGTX) currently generate any revenue from its biotechnology programs?

No. Agentix Corp reported no revenue for the three months ended June 30, 2026, and for the comparable 2025 quarter. The company remains a clinical-stage biotechnology enterprise focused on metabolic disease and relies on external funding to support operations.

AI-generated analysis. How Rhea-AI works. Not financial advice.

10-Q Quarterly Reports: What Changes Quarter to Quarter →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/10/2026 - 06:01 AM Accepted by SEC EDGAR 08/07/2026 - 05:45 PM Learn about SEC filing dates

0001603345false--03-31Q120270.00150000000400669514006695140066951357102falsefalsefalsefalse000016033452026-04-012026-06-300001603345agtx:SoftwareSubscriptionMember2026-06-300001603345agtx:SoftwareSubscriptionMember2026-03-310001603345agtx:SoftwareSubscriptionMember2026-04-012026-06-300001603345agtx:ServicesMember2026-06-300001603345agtx:ServicesMember2026-03-310001603345agtx:ServicesMember2026-04-012026-06-300001603345agtx:GraysPeakMember2023-01-012023-01-150001603345agtx:GraysPeakMember2023-01-150001603345agtx:GraysPeakMember2023-06-150001603345agtx:PresidentandBoardmemberMember2026-03-310001603345agtx:SBSManagementMember2025-04-012025-06-300001603345agtx:SBSManagementMember2026-04-012026-06-300001603345agtx:GraysPeakMember2026-03-310001603345agtx:GraysPeakMember2026-06-300001603345agtx:SBSManagementMember2026-03-310001603345agtx:SBSManagementMember2026-06-300001603345agtx:PresidentandBoardmemberMember2026-06-300001603345agtx:ClinicalResearchMember2026-06-300001603345agtx:ClinicalResearchMember2026-03-310001603345agtx:GSLHealthcareMember2026-06-300001603345us-gaap:RetainedEarningsMember2026-06-300001603345us-gaap:AccumulatedOtherComprehensiveIncomeMember2026-06-300001603345us-gaap:AdditionalPaidInCapitalMember2026-06-300001603345agtx:CommonStocktobeIssuedMember2026-06-300001603345us-gaap:CommonStockMember2026-06-300001603345us-gaap:RetainedEarningsMember2026-04-012026-06-300001603345us-gaap:AccumulatedOtherComprehensiveIncomeMember2026-04-012026-06-300001603345us-gaap:AdditionalPaidInCapitalMember2026-04-012026-06-300001603345agtx:CommonStocktobeIssuedMember2026-04-012026-06-300001603345us-gaap:CommonStockMember2026-04-012026-06-300001603345us-gaap:RetainedEarningsMember2026-03-310001603345us-gaap:AccumulatedOtherComprehensiveIncomeMember2026-03-310001603345us-gaap:AdditionalPaidInCapitalMember2026-03-310001603345agtx:CommonStocktobeIssuedMember2026-03-310001603345us-gaap:CommonStockMember2026-03-3100016033452025-06-300001603345us-gaap:RetainedEarningsMember2025-06-300001603345us-gaap:AccumulatedOtherComprehensiveIncomeMember2025-06-300001603345us-gaap:AdditionalPaidInCapitalMember2025-06-300001603345agtx:CommonStocktobeIssuedMember2025-06-300001603345us-gaap:CommonStockMember2025-06-300001603345us-gaap:RetainedEarningsMember2025-04-012025-06-300001603345us-gaap:AccumulatedOtherComprehensiveIncomeMember2025-04-012025-06-300001603345us-gaap:AdditionalPaidInCapitalMember2025-04-012025-06-300001603345agtx:CommonStocktobeIssuedMember2025-04-012025-06-300001603345us-gaap:CommonStockMember2025-04-012025-06-3000016033452025-03-310001603345us-gaap:RetainedEarningsMember2025-03-310001603345us-gaap:AccumulatedOtherComprehensiveIncomeMember2025-03-310001603345us-gaap:AdditionalPaidInCapitalMember2025-03-310001603345agtx:CommonStocktobeIssuedMember2025-03-310001603345us-gaap:CommonStockMember2025-03-3100016033452025-04-012025-06-3000016033452026-03-3100016033452026-06-3000016033452026-08-07iso4217:USDxbrli:sharesiso4217:USDxbrli:sharesxbrli:pure

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 10-Q

(MARK ONE)

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended June 30, 2026

OR

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from _______ to ______

Commission File No. 000-55383

AGENTIX CORP.

(Exact name of registrant as specified in its charter)

Nevada		46-2876282
(State or other jurisdiction of		(I.R.S. Employer
incorporation or organization)		Identification No.)

32932 Pacific Coast Highway, #14-254

Dana Point, California 92629

(Address of principal executive offices, zip code)

(321) 299-2014

(Registrant’s telephone number, including area code)

_____________________________________________________

(Former name, former address and former fiscal year, if changed since last report)

Securities registered pursuant to Section 12(b) of the Act:

Title of each class Trading Symbol(s) Name of each exchange on which registered

Indicate by check mark whether the issuer (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒    No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒    No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act. (check one):

Large accelerated filer	☐	Accelerated filer	☐
Non-accelerated filer	☒	Smaller reporting company	☒
		Emerging growth company	☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒

Indicate by check mark whether the registrant is a shell company (as defined in Exchange Act Rule 12b-2 of the Exchange Act): Yes ☐     No ☒

As of August 7, 2026, there were 40,066,951 shares of common stock, $0.001 par value per share, outstanding.

AGENTIX CORP.

QUARTERLY REPORT ON FORM 10-Q

FOR THE PERIOD ENDED JUNE 30, 2026

INDEX

Index			Page
Part I. Financial Information
Item 1.	Financial Statements		F-1
	Consolidated Balance Sheets at June 30, 2026 (Unaudited) and March 31, 2026 (Audited).		F-1
	Unaudited Consolidated Statements of Operations for the three months ended June 30, 2026 and 2025.		F-2
	Unaudited Consolidated Statements of Changes in Stockholders’ Deficit for the three months ended June 30, 2026 and 2025.		F-3
	Unaudited Consolidated Statements of Cash Flows for the three months ended June 30, 2026 and 2025.		F-4
	Notes to Financial Statements (Unaudited).		F-5
Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations.		4
Item 3.	Quantitative and Qualitative Disclosures About Market Risk.		6
Item 4.	Controls and Procedures.		6
Part II. Other Information
Item 1.	Legal Proceedings.		7
Item 1A.	Risk Factors		7
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds.		7
Item 3.	Defaults Upon Senior Securities.		7
Item 4.	Mine Safety Disclosures.		7
Item 5.	Other Information.		7
Item 6.	Exhibits.		8
Signatures			9

2

Table of Contents

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

This Quarterly Report on Form 10-Q of Agentix Corp., a Nevada corporation (the “Company”), contains “forward-looking statements,” as defined in the United States Private Securities Litigation Reform Act of 1995. In some cases, you can identify forward-looking statements by terminology such as “may”, “will”, “should”, “could”, “expects”, “plans”, “intends”, “anticipates”, “believes”, “estimates”, “predicts”, “potential” or “continue” or the negative of such terms and other comparable terminology. These forward-looking statements include, without limitation, statements about our market opportunity, our strategies, competition, expected activities and expenditures as we pursue our business plan, and the adequacy of our available cash resources. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements. Actual results may differ materially from the predictions discussed in these forward-looking statements. The economic environment within which we operate could materially affect our actual results. Additional factors that could materially affect these forward-looking statements and/or predictions include, among other things: the Company’s need for and ability to obtain additional financing, product demand, market and customer acceptance, competition, public health crises, pricing and development difficulties, as well as general industry and market conditions and growth rates, general economic conditions, and other factors over which we have little or no control; and other factors discussed in the Company’s filings with the Securities and Exchange Commission (“SEC”).

Our management has included projections and estimates in this Form 10-Q, which are based primarily on management’s experience in the industry, assessments of our results of operations, discussions and negotiations with third parties and a review of information filed by our competitors with the SEC or otherwise publicly available. We caution readers not to place undue reliance on any such forward-looking statements, which speak only as of the date made. We disclaim any obligation subsequently to revise any forward-looking statements to reflect events or circumstances after the date of such statements or to reflect the occurrence of anticipated or unanticipated events.

3

Table of Contents

PART I. FINANCIAL INFORMATION

ITEM 1. FINANCIAL STATEMENTS.

Agentix Corp. and Subsidiaries

Consolidated Balance Sheets

		June 30, 2026				March 31, 2026
		(Unaudited)
Assets
Current Assets
Cash		$	38			$	771
Prepaid expense and other current assets			-				-
Total current assets			38				771
Total assets		$	38			$	771
Liabilities and Stockholders' Deficit
Current Liabilities
Accounts payable		$	713,344			$	715,870
Accounts payable - related parties			2,455,276				2,383,073
Note payable - related party			379,700				353,450
Accrued expenses			165,511				143,889
Total current liabilities			3,713,831				3,596,282
Long Term Liabilities			-				-
Total liabilities			3,713,831				3,596,282
Commitments and Contingencies			-				-
Stockholders' Deficit
Common stock par value $0.001: 50,000,000 shares authorized; 40,066,951 shares issued and outstanding as of June 30, 2026 and March 31, 2026			40,067				40,067
Common stock to be issued (357,102 shares at June 30, 2026 and March 31, 2026)			53,535				53,535
Additional paid-in capital			3,288,296				3,288,296
Accumulated other comprehensive income			29,147				29,755
Accumulated deficit			(7,124,838	)			(7,007,164	)
Total stockholders' deficit			(3,713,793	)			(3,595,511	)
Total liabilities and stockholders' deficit		$	38			$	771

See accompanying notes to the unaudited consolidated financial statements.

F-1

Table of Contents

Agentix Corp. and Subsidiaries

Unaudited Consolidated Statements of Operations

		Three Months				Three Months
		Ended				Ended
		June 30, 2026				June 30, 2025
Operating Expenses
Professional fees		$	62,084			$	82,625
Research and development			16,635				100,000
General and administrative expenses			16,785				17,717
Total operating expenses			95,504				200,342
Loss from operations			(95,504	)			(200,342	)
Other (income) expense
Foreign exchange gain (loss)			-				(15,140	)
Interest expense, net			22,170				21,226
Other income			-				(20,604	)
Other loss (income), net			22,170				(14,518	)
Loss before income tax provision			(117,674	)			(185,824	)
Income tax provision			-				-
Net loss		$	(117,674	)		$	(185,824	)
Other comprehensive income
Change in foreign currency translation, net of tax			(608	)			18,307
Total comprehensive loss		$	(118,282	)		$	(167,517	)
Loss per share
- Basic and diluted		$	(0.00	)		$	(0.00	)
Weighted average common shares outstanding
- Basic and diluted			40,066,951				40,066,951

See accompanying notes to the unaudited consolidated financial statements.

F-2

Table of Contents

Agentix Corp. and Subsidiaries

Unaudited Consolidated Statements of Changes in Stockholders’ Deficit

For the Three Months Ended June 30, 2026 and 2025

		Common stock par value $0.001								Common				Additional				Other
		Number of Shares				Amount				Stock to be Issued				Paid-in Capital				Comprehensive Income (Loss)				Accumulated Deficit				Stockholders' Deficit
Balance, March 31, 2025			40,066,951			$	40,067			$	53,535			$	3,288,296			$	35,381			$	(6,521,528	)		$	(3,104,249	)
Foreign exchange translation gain			-				-				-				-				18,307				-				18,307
Net Loss			-				-				-				-				-				(185,824	)			(185,824	)
Balance, June 30, 2025			40,066,951			$	40,067			$	53,535			$	3,288,296			$	53,688			$	(6,707,352	)		$	(3,271,766	)
Balance, March 31, 2026			40,066,951			$	40,067			$	53,535			$	3,288,296			$	29,755			$	(7,007,164	)		$	(3,595,511	)
Foreign exchange translation loss			-				-				-				-				(608	)			-				(608	)
Net Loss			-				-				-				-				-				(117,674	)			(117,674	)
Balance, June 30, 2026			40,066,951			$	40,067			$	53,535			$	3,288,296			$	29,147			$	(7,124,838	)		$	(3,713,793	)

See accompanying notes to the unaudited consolidated financial statements.

F-3

Table of Contents

Agentix Corp. and Subsidiaries

Unaudited Consolidated Statements of Cash Flows

		Three Months				Three Months
		Ended				Ended
		June 30, 2026				June 30, 2025
Cash Flows from Operating Activities
Net loss		$	(117,674	)		$	(185,824	)
Adjustments to reconcile net loss to net cash used in operating activities:
Changes in operating assets and liabilities:
Prepayments and other current assets			1				95,797
Accrued expenses, accounts payable and accounts payable-related party			91,301				(28,344	)
Net Cash Provided by (Used in) Operating Activities			(26,372	)			(118,371	)
Cash Flows from Investing Activities			-				-
Cash Flows from Financing Activities
Proceeds from issuance of debt			26,250				100,000
Net Cash Provided by Financing Activities			26,250				100,000
Effects of Foreign Exchange Rate Changes on Cash			(611	)			18,306
Net Change in Cash			(733	)			(65	)
Cash - beginning of reporting period			771				4,477
Cash - end of reporting period		$	38			$	4,412
Supplemental disclosure of cash flow information:
Interest paid		$	-			$	-
Income tax paid		$	-			$	-

See accompanying notes to the unaudited consolidated financial statements.

F-4

Table of Contents

Note 1 - Organization and Basis of Presentation

Description of the Company

FairWind Energy, Inc. (the “Company”) was incorporated on April 18, 2013 under the laws of the State of Nevada. Effective June 17, 2019, the Company changed its name to Agentix Corp. In March 2022, the Company changed its fiscal year end from August to March.

The Company is a clinical-stage biotechnology company developing therapeutic agents for the treatment of metabolic disease like Type 2 diabetes mellitus, obesity, non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH).

Going Concern

The Company’s unaudited consolidated financial statements have been prepared assuming that it will continue as a going concern, which contemplates continuity of operations, realization of assets, and liquidation of liabilities in the normal course of business.

As reflected in the unaudited consolidated financial statements, the Company had an accumulated deficit of $7,124,838 as of June 30, 2026, a net loss of $117,674 and net cash used in operating activities of $26,372 for the three months ended June 30, 2026, and negative working capital of $3,713,793 as of June 30, 2026. Cash on hand as of June 30, 2026 was $38. These factors raise substantial doubt about the Company’s ability to continue as a going concern.

The Company is attempting to commence operations and generate sufficient revenue; however, the Company’s cash position is not sufficient to support its daily operations, and it will need further funding. The ability of the Company to continue as a going concern is dependent upon its ability to further implement its business plan and generate sufficient revenue and its ability to raise additional funds.

The unaudited consolidated financial statements do not include any adjustments related to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.

Principles of Consolidation

The unaudited consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries, GSL Healthcare, Inc., AB Merger LLC, Agentix Australia Pty Ltd, and Applied Biopharma, all of which are 100% owned by the Company. Intercompany transactions and balances have been eliminated in consolidation. Except for Agentix Australia Pty Ltd, the Company’s subsidiaries had no material operations or activity during the periods presented.

Note 2 - Significant and Critical Accounting Policies and Practices

Basis of Presentation

The accompanying unaudited consolidated financial statements and related notes have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”), and with the rules and regulations of the United States Securities and Exchange Commission (“SEC”) applicable to Form 10-Q and Article 8 of Regulation S-X. Accordingly, they do not include all information and footnotes required by U.S. GAAP for complete financial statements. The unaudited interim consolidated financial statements reflect all adjustments (consisting of normal recurring accruals) that, in the opinion of management, are necessary for a fair statement of the results for the interim periods presented. Unaudited interim results are not necessarily indicative of results for the full fiscal year. These financial statements should be read in conjunction with the audited consolidated financial statements and notes included in the Company’s Annual Report on Form 10-K for the fiscal year ended March 31, 2026.

Prepayment

Prepayments were $0 as of June 30, 2026 and March 31, 2026.

F-5

Table of Contents

Fair Value of Financial Instruments

The Company follows paragraph 825-10-50-10 of the FASB Accounting Standards Codification for disclosures about fair value of its financial instruments and paragraph 820-10-35-37 of the FASB Accounting Standards Codification (“Paragraph 820-10-35-37”) to measure the fair value of its financial instruments. Paragraph 820-10-35-37 establishes a framework for measuring fair value in generally accepted accounting principles (GAAP) and expands disclosures about fair value measurements. To increase consistency and comparability in fair value measurements and related disclosures, Paragraph 820-10-35-37 establishes a fair value hierarchy which prioritizes the inputs to valuation techniques used to measure fair value into three (3) broad levels. The fair value hierarchy gives the highest priority to quoted prices (unadjusted) in active markets for identical assets or liabilities and the lowest priority to unobservable inputs. The three (3) levels of fair value hierarchy defined by Paragraph 820-10-35-37 are described below:

Level 1	Quoted market prices available in active markets for identical assets or liabilities as of the reporting date.
Level 2	Pricing inputs other than quoted prices in active markets included in Level 1, which are either directly or indirectly observable as of the reporting date.
Level 3	Pricing inputs that are generally unobservable inputs and not corroborated by market data.

Financial assets are considered Level 3 when their fair values are determined using pricing models, discounted cash flow methodologies or similar techniques and at least one significant model assumption or input is unobservable.

The fair value hierarchy gives the highest priority to quoted prices (unadjusted) in active markets for identical assets or liabilities and the lowest priority to unobservable inputs. If the inputs used to measure the financial assets and liabilities fall within more than one level described above, the categorization is based on the lowest level input that is significant to the fair value measurement of the instrument.

The carrying amounts of the Company’s financial assets and liabilities, such as cash, accounts payable and accrued expenses approximate their fair values because of the short maturity of these instruments.

Research and Development

The Company follows paragraph 730-10-25-1 of the FASB Accounting Standards Codification (formerly Statement of Financial Accounting Standards No. 2 “Accounting for Research and Development Costs”) and paragraph 730-20-25-11 of the FASB Accounting Standards Codification (formerly Statement of Financial Accounting Standards No. 68 “Research and Development Arrangements”) for research and development costs. Research and development costs are charged to expense as incurred. Research and development costs consist primarily of remuneration for material and testing costs for research and development.

Related Parties

The Company follows subtopic 850-10 of the FASB Accounting Standards Codification for the identification of related parties and disclosure of related party transactions.

Pursuant to Section 850-10-20 the related parties include a. affiliates (“Affiliate” means, with respect to any specified Person, any other Person that, directly or indirectly through one or more intermediaries, controls, is controlled by or is under common control with such Person, as such terms are used in and construed under Rule 405 under the Securities Act) of the Company; b. entities for which investments in their equity securities would be required, absent the election of the fair value option under the Fair Value Option Subsection of Section 825–10–15, to be accounted for by the equity method by the investing entity; c. trusts for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of management; d. principal owners of the Company; e. management of the Company; f. other parties with which the Company may deal if one party controls or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests; and g. other parties that can significantly influence the management or operating policies of the transacting parties or that have an ownership interest in one of the transacting parties and can significantly influence the other to an extent that one or more of the transacting parties might be prevented from fully pursuing its own separate interests.

The financial statements shall include disclosures of material related party transactions, other than compensation arrangements, expense allowances, and other similar items in the ordinary course of business. However, disclosure of transactions that are eliminated in the preparation of consolidated or combined financial statements is not required in those statements. The disclosures shall include: a. the nature of the relationship(s) involved; b. a description of the transactions, including transactions to which no amounts or nominal amounts were ascribed, for each of the periods for which income statements are presented, and such other information deemed necessary to an understanding of the effects of the transactions on the financial statements; c. the dollar amounts of transactions for each of the periods for which income statements are presented and the effects of any change in the method of establishing the terms from that used in the preceding period; and d. amounts due from or to related parties as of the date of each balance sheet presented and, if not otherwise apparent, the terms and manner of settlement.

F-6

Table of Contents

Deferred Tax Assets and Income Tax Provision

The Company accounts for income taxes under Section 740-10-30 of the FASB Accounting Standards Codification. Deferred income tax assets and liabilities are determined based upon differences between the financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. Deferred tax assets are reduced by a valuation allowance to the extent management concludes it is more likely than not that the assets will not be realized. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the statements of operations in the period that includes the enactment date.

The Company adopted section 740-10-25 of the FASB Accounting Standards Codification (“Section 740-10-25”). Section 740-10-25 addresses the determination of whether tax benefits claimed or expected to be claimed on a tax return should be recorded in the financial statements. Under Section 740-10-25, the Company may recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by the taxing authorities, based on the technical merits of the position. The tax benefits recognized in the financial statements from such a position should be measured based on the largest benefit that has a greater than fifty percent (50%) likelihood of being realized upon ultimate settlement. Section 740-10-25 also provides guidance on de-recognition, classification, interest and penalties on income taxes, accounting in interim periods and requires increased disclosures.

Earnings per Share

Earnings per share (“EPS”) are the amount of earnings attributable to each share of common stock. For convenience, the term is used to refer to either earnings or loss per share. EPS is computed pursuant to section 260-10-45 of the FASB Accounting Standards Codification. Pursuant to ASC Paragraphs 260-10-45-10 through 260-10-45-16, basic EPS shall be computed by dividing income available to common stockholders (the numerator) by the weighted-average number of common shares outstanding (the denominator) during the period. Income available to common stockholders shall be computed by deducting both the dividends declared in the period on preferred stock (whether or not paid) and the dividends accumulated for the period on cumulative preferred stock (whether or not earned) from income from continuing operations (if that amount appears in the income statement) and also from net income. The computation of diluted EPS is similar to the computation of basic EPS except that the denominator is increased to include the number of additional common shares that would have been outstanding if the dilutive potential common shares had been issued during the period to reflect the potential dilution that could occur from common shares issuable through contingent shares issuance arrangement, stock options or warrants.

Pursuant to ASC Paragraphs 260-10-45-45-21 through 260-10-45-45-23 Diluted EPS shall be based on the most advantageous conversion rate or exercise price from the standpoint of the security holder. The dilutive effect of outstanding call options and warrants (and their equivalents) issued by the reporting entity shall be reflected in diluted EPS by application of the treasury stock method unless the provisions of paragraphs 260-10-45-35 through 45-36 and 260-10-55-8 through 55-11 require that another method be applied. Equivalents of options and warrants include non-vested stock granted to employees, stock purchase contracts, and partially paid stock subscriptions (see paragraph 260–10–55–23). Anti-dilutive contracts, such as purchased put options and purchased call options, shall be excluded from diluted EPS. Under the treasury stock method: a. Exercise of options and warrants shall be assumed at the beginning of the period (or at time of issuance, if later) and common shares shall be assumed to be issued. b. The proceeds from exercise shall be assumed to be used to purchase common stock at the average market price during the period. (See paragraphs 260-10-45-29 and 260-10-55-4 through 55-5.) c. The incremental shares (the difference between the number of shares assumed issued and the number of shares assumed purchased) shall be included in the denominator of the diluted EPS computation.

There were no dilutive common shares for the three months ended June 30, 2026 and 2025.

Stock-Based Payments

Stock-based compensation is accounted for based on the requirements of the Share-Based Payment Topic of ASC 718, “Compensation — Stock Compensation” (“ASC 718”), which requires recognition in the financial statements of the cost of employee and director services received in exchange for an award of equity instruments over the period the employee or director is required to perform the services in exchange for the award (presumptively, the vesting period). ASC 718 also requires measurement of the cost of employee and director services received in exchange for an award based on the grant-date fair value of the award.

For non-employees, the Company follows ASU No. 2018-07, Compensation - Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting. Under the ASU No. 2017-07, most of the guidance on stock payments to nonemployees is aligned with the requirements for share-based payments granted to employees. As such, most of the guidance in ASC 718 associated with employee share-based payments, including most requirements related to classification and measurement, applies to nonemployee share-based payment arrangements.

No stock options or warrants were issued or outstanding as of June 30, 2026 and March 31, 2026.

F-7

Table of Contents

Recent Accounting Pronouncements

There have been no material changes in accounting pronouncements during the three months ended June 30, 2026 compared with the recent accounting pronouncements described in the Company’s Annual Report on Form 10-K for the fiscal year ended March 31, 2026.

Commitment and Contingencies

The Company accounts for contingencies in accordance with ASC 450-20, Loss Contingencies. Certain conditions may exist as of the date the financial statements are issued that may result in a loss to the Company, but which will only be resolved when one or more future events occur or fail to occur. The Company assesses such contingent liabilities based on available information, and such assessment inherently involves the exercise of judgment.

In assessing loss contingencies related to pending legal proceedings or unasserted claims that may result in legal proceedings, the Company evaluates the perceived merits of the matter, the likelihood of an unfavorable outcome, and the amount of relief sought or expected to be sought. If the assessment indicates that it is probable that a loss has been incurred and the amount of the liability can be reasonably estimated, the Company accrues the estimated liability in the financial statements. If the assessment indicates that a potential material loss contingency is not probable but is reasonably possible, or is probable but the amount cannot be reasonably estimated, the Company discloses the nature of the contingency and an estimate of the possible loss or range of loss, if such estimate can be made and is material. Loss contingencies considered remote are generally not disclosed unless they involve guarantees.

The Company has received correspondence from a vendor alleging that approximately $44,991 remains outstanding in connection with prior services allegedly provided to Agentix Australia Pty Ltd. The vendor has indicated that it has commenced debt recovery action and may pursue formal legal proceedings if the amount is not resolved. Management disputes certain aspects of the vendor’s claim, including whether the amounts are valid and payable; however, the Company has accrued the asserted amount in the accompanying consolidated financial statements.

As of June 30, 2026, other than the matter described above, the Company is not aware of any material pending or threatened claims, commitments, or contingencies that would require additional accrual or disclosure in the consolidated financial statements.

Segment Reporting

The Chief Operating Decision Maker (“CODM”) for the Company is the Chief Executive Officer (the “CEO”). The Company’s CEO reviews operating results on an aggregate basis and manages the Company’s operations as a whole for the purpose of evaluating financial performance and allocating resources. This decision-making process reflects the way in which financial information is regularly reviewed and used by the CODM to evaluate performance, set operational targets, forecast future financial results, and allocate resources. Accordingly, the Company has determined that it has a single reportable and operating segment.

The Company’s CODM assesses financial performance and allocates resources based on operating results which are also reported on the accompanying consolidated statements of operations. The measure of segment assets is reported on the balance sheet as total consolidated assets. The CODM utilizes consolidated operating results by comparing actual results against budgeted amounts. As part of this process, consolidated net loss is a critical performance measure used to evaluate the Company’s operating performance and guide strategic decisions and resource allocations, including additional investments in research and development.

F-8

Table of Contents

Note 3 - Related Parties

SBS Management LLC

During the three months ended June 30, 2026 and 2025, SBS Management LLC, a company controlled by Mr. Scott Stevens, a shareholder of the Company, received management consulting fees and made advances to the Company to pay certain expenses. These expenses totaled $71,768 and $54,000, respectively. As of June 30, 2026 and March 31, 2026, $1,556,746 and $1,484,978, respectively, were included in accounts payable - related parties on the accompanying consolidated balance sheets. These advances are unsecured, non-interest bearing, and have no formal terms of repayment.

Gray’s Peak Capital

During the three months ended June 30, 2026 and 2025, Gray’s Peak Capital (“Gray’s Peak”), a company founded by a shareholder of the Company, made advances to the Company to cover certain operating expenses. These advances are unsecured, non-interest bearing, and have no formal terms of repayment. As of June 30, 2026 and March 31, 2026, amounts due to Gray’s Peak were $527,986 and $527,248, respectively, and were included in accounts payable - related parties on the accompanying consolidated balance sheets.

Gray’s Peak Capital – Note Payable

On January 15, 2023 and June 15, 2023, the Company entered into two separate Mezzanine Secured Notes (the “Notes”) in principal amounts of up to $200,000 and $500,000, respectively, with Gray’s Peak Private Credit LLC. For 30 days after the date of each Note, the Note bears interest at 7.5%. After the 30th day, the Note bears interest at 2% per month until paid in full. The Notes originally matured on the fourth and sixth month anniversaries of the respective loan dates. The Company may prepay any portion of a Note without premium or penalty. The January 15, 2023 borrowings were repaid in September 2023. The June 15, 2023 Note has been extended to September 30, 2026.

The Notes are secured by a pledge by the Company of favor of Gray’s Peak of all of the assets and property of the Company, including without limitation all R&D tax credits, goods, tangible property, machinery, owned equipment, furniture, fixtures, vehicles, parts, accounts, deposit accounts, letter-of-credit rights, chattel paper, contract rights, documents, instruments, investment property, choses in action, general intangibles, goodwill and intellectual property, of any kind or nature, wherever located, in which Company has an interest now or in the future, and which are now existing or hereafter created or acquired, together with any and all additions, replacements, accessions and substitutions thereto or therefore, and any proceeds thereof excluding equipment leased by the Company (collectively called the “Collateral”). Gray’s Peak interest is senior to the unsecured debt or lenders of the Company and the Company’s equity holders. Upon the occurrence of any Event of Default, as defined in the agreement, the principal sum, all accrued and unpaid interest owing thereon and all costs and expenses payable pursuant to this Note, shall, at the sole option of Gray’s Peak and with submission of written notice, become immediately due and payable.

As of June 30, 2026 and March 31, 2026, the principal balance outstanding was $379,700 and $353,450, respectively. The Notes were included in note payable - related party on the accompanying consolidated balance sheets. Accrued interest of $164,408 and $143,889 was included in accrued expenses as of June 30, 2026 and March 31, 2026, respectively.

Management

As of June 30, 2026 and March 31, 2026, $433,497 and $433,497, respectively, was included in accounts payable - related parties on the accompanying consolidated balance sheets.

F-9

Table of Contents

Note 4 - Equity

As of June 30, 2026 and March 31, 2026, the Company had authorized 50,000,000 shares of common stock with a par value of $0.001 per share and had 40,066,951 shares issued and outstanding at each date.

During the three months ended June 30, 2026, the Company did not issue any shares of common stock for services.

Shares to be Issued

The Company had previously granted 250,000 shares of common stock for services previously provided. As of June 30, 2026 and March 31, 2026, 250,000 and 250,000 of these shares, respectively, had not been issued and were included in common stock to be issued in the consolidated balance sheets.

The Company had previously granted 307,102 shares of common stock in exchange for a one-year software subscription. As of June 30, 2026 and March 31, 2026, 107,102 and 107,102 shares, respectively, had not been issued and were included in common stock to be issued in the consolidated balance sheets.

Note 5 - Subsequent Events

In accordance with ASC 855, the Company has analyzed its operations subsequent to June 30, 2026 through the date these financial statements were issued and has determined that it does not have any other material subsequent events to disclose in these financial statements. 

F-10

Table of Contents

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS.

The following information should be read in conjunction with (i) the unaudited consolidated financial statements of Agentix Corp., a Nevada corporation (the “Company”), and the notes thereto appearing elsewhere in this Form 10-Q and (ii) the more detailed business information and audited consolidated financial statements and related notes included in the Company’s Annual Report on Form 10-K for the fiscal year ended March 31, 2026. Statements in this section and elsewhere in this Form 10-Q that are not statements of historical or current fact constitute forward-looking statements.

Company Overview

We were incorporated in the State of Nevada on April 18, 2013 and we initially established a fiscal year end of August 31. In March 2022, we changed our year end to March 31.

CRITICAL ACCOUNTING POLICIES

The discussion and analysis of our financial condition and results of operations are based on our consolidated financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States (“US GAAP”). The preparation of these consolidated financial statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. On an ongoing basis, we evaluate our estimates based on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions. For the periods presented, we concluded that no accounting policies required such extensive judgment or complexity that they should be classified as critical to understanding our financial condition or operating results.

Basis of Accounting

Our unaudited consolidated financial statements and related notes have been prepared in accordance with U.S. GAAP and with the rules and regulations of the SEC applicable to Form 10-Q and Article 8 of Regulation S-X. Accordingly, they do not include all information and footnotes required by U.S. GAAP for complete financial statements. The unaudited interim financial statements reflect all adjustments (consisting of normal recurring accruals) that, in the opinion of management, are necessary for a fair statement of the results for the interim periods presented. Unaudited interim results are not necessarily indicative of results for the full fiscal year. These financial statements should be read in conjunction with the audited consolidated financial statements and notes included in our Annual Report on Form 10-K for the fiscal year ended March 31, 2026.

Recent Accounting Pronouncements

We do not expect the adoption of recently issued accounting pronouncements to have a significant impact on its results of operations, financial position or cash flow.

RESULTS OF OPERATIONS

Three Months Ended June 30, 2026 as compared to Three Months Ended June 30, 2025:

We recorded no revenue during the three months ended June 30, 2026 and 2025.

For the three months ended June 30, 2026, professional fees were $62,084 compared with $82,625 for the three months ended June 30, 2025, a decrease of $20,541. The decrease was primarily due to lower professional service costs during the current period.

For the three months ended June 30, 2026, research and development expenses were $16,635 compared with $100,000 for the same period in 2025, a decrease of $83,365. The decrease was mainly related to lower research and development activity during the current period.

For the three months ended June 30, 2026, general and administrative expenses were $16,785 compared with $17,717 for the three months ended June 30, 2025, a decrease of $932, reflecting slightly lower administrative costs.

4

Table of Contents

The Company recorded no foreign exchange gain or loss for the three months ended June 30, 2026, compared with a foreign exchange gain of $15,140 for the three months ended June 30, 2025, a $15,140 unfavorable variance due primarily to fluctuations in currency exchange rates.

For the three months ended June 30, 2026, interest expense, net was $22,170 compared with $21,226 for the three months ended June 30, 2025, an increase of $944 related to higher debt balances and related accrued interest.

For the three months ended June 30, 2026, other income was $0 compared with $20,604 for the three months ended June 30, 2025. The prior-year amount related to a gain on settlement of payables.

As a result, net loss for the three months ended June 30, 2026 was $117,674 compared with a net loss of $185,824 for the three months ended June 30, 2025. Other comprehensive loss for the three months ended June 30, 2026 included an unfavorable foreign currency translation adjustment of $608, compared with a favorable adjustment of $18,307 for the prior-year period, resulting in total comprehensive loss of $118,282 and $167,517, respectively.

Liquidity and Capital Resources

Our unaudited consolidated financial statements have been prepared assuming that we will continue as a going concern, which contemplates continuity of operations, realization of assets and liquidation of liabilities in the normal course of business. As reflected in our unaudited consolidated financial statements for the three months ended June 30, 2026, we had an accumulated deficit of $7,124,838, a net loss of $117,674, net cash used in operating activities of $26,372, negative working capital of $3,713,793, cash of $38, and total current liabilities of $3,713,831 as of June 30, 2026. These factors raise substantial doubt about our ability to continue as a going concern.

We are attempting to commence operations and generate sufficient revenue; however, our cash position is not sufficient to support our daily operations. As such, we will need to raise funds to complete our plan of operation and fund our ongoing operational expenses for the next 12 months. Additional funding will likely come from equity financing from the sale of our common stock or debt financing. If we are successful in completing an equity financing, existing shareholders will experience dilution of their interest in our Company and if we obtain debt financing, the terms of any such debt financing may not be favorable to existing shareholders. We cannot provide investors with any assurance that we will be able to raise sufficient funding from the sale of our common stock or obtaining debt to fund our development activities and ongoing operational expenses. In the absence of such financing, our business will likely fail. There are no assurances that we will be able to achieve further sales of our common stock or any other form of additional financing. If we are unable to achieve the financing necessary to continue our plan of operations, then we will not be able to continue our development to complete our plan of operation and our business will fail.

Off-Balance Sheet Arrangements

The Company has no off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on the financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that is material to stockholders.

Subsequent Events

In accordance with ASC 855, the Company has analyzed its operations subsequent to June 30, 2026 through the date these financial statements were issued and has determined that it does not have any other material subsequent events to disclose in these financial statements. 

5

Table of Contents

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK.

As a smaller reporting company (as defined in Rule 12b-2 of the Exchange Act), we are not required to provide the information called for by this Item 3.

ITEM 4. CONTROLS AND PROCEDURES.

DISCLOSURE CONTROLS AND PROCEDURES

Under the supervision and with the participation of our management, including Riazul (Rehan) Huda, our Chief Executive Officer and Chief Financial Officer, we evaluated the effectiveness of the design and operation of our disclosure controls and procedures, as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as of June 30, 2026. Disclosure controls and procedures are designed to ensure that material information required to be included in our SEC reports is recorded, processed, summarized and reported within the time periods specified in SEC rules and forms and is communicated to management, including our principal executive and financial officer, as appropriate to allow timely decisions regarding required disclosure. Based on this evaluation, our principal executive officer and principal financial officer concluded that our disclosure controls and procedures were not effective as of June 30, 2026.

There were no changes in the Company’s internal controls over financial reporting during the most recently completed fiscal quarter that have materially affected or are reasonably likely to materially affect the Company’s internal control over financial reporting.

6

Table of Contents

PART II. OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS.

The Company is not currently subject to any legal proceedings. From time to time, the Company may become subject to litigation or proceedings in connection with its business, as either a plaintiff or defendant. There are no such pending legal proceedings to which the Company is a party that, in the opinion of management, is likely to have a material adverse effect on the Company’s business, financial condition or results of operations.

ITEM 1A. RISK FACTORS

As a smaller reporting company (as defined in Rule 12b-2 of the Exchange Act), we are not required to provide the information called for by this Item 1A.

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS.

None.

ITEM 3. DEFAULTS UPON SENIOR SECURITIES.

None.

ITEM 4. MINE SAFETY DISCLOSURES.

None.

ITEM 5. OTHER INFORMATION.

None.

7

Table of Contents

ITEM 6. EXHIBITS.

(a) Exhibits required by Item 601 of Regulation SK.:

Number		Description
3.1.1		Articles of Incorporation (incorporated by reference to Exhibit 3.1.1 to the Registrant Annual Report on Form 10-Km SEC File No. 000-55383 filed August 30, 2024)
3.1.2		Certificate of Amendment to Articles of Incorporation (incorporated by reference to Exhibit 3.1.1 to the Registrant Annual Report on Form 10-Km SEC File No. 000-55383 filed August 30, 2024)
3.1.3		Certificate of Change (incorporated by reference to Exhibit 3.1.1 to the Registrant Annual Report on Form 10-Km SEC File No. 000-55383 filed August 30, 2024)
3.2		Bylaws (incorporated by reference to Exhibit 3.2.1 to the Registrant Annual Report on Form 10-Km SEC File No. 000-55383 filed August 30, 2024)
31.1		Certification of Principal Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
31.2		Certification of Principal Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
32.1*		Certification of Principal Executive Officer and Principal Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
101.INS *		Inline XBRL Instance Document
101.SCH *		Inline XBRL Taxonomy Extension Schema Document
101.CAL *		Inline XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF *		Inline XBRL Taxonomy Extension Definition Linkbase Document
101.LAB *		Inline XBRL Taxonomy Extension Label Linkbase Document
101.PRE *		Inline XBRL Taxonomy Extension Presentation Linkbase Document
104*		Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)

_____________

*Furnished, not filed.

8

Table of Contents

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	AGENTIX CORP.
Date: August 7, 2026	By:	/s/ Riazul (Rehan) Huda
		Name: Riazul (Rehan) Huda
		Title: Director
		(principal executive officer, principal accounting officer and principal financial officer)

9